November 24, 2016 - By Ellis Scott · 0 Comments
The stock of Atossa Genetics Incorporated (NASDAQ:ATOS) registered a decrease of 11.7% in short interest. ATOS’s total short interest was 40,000 shares in November as published by FINRA. Its down 11.7% from 45,300 shares, reported previously. With 64,700 shares average volume, it will take short sellers 1 days to cover their ATOS’s short positions. The short interest to Atossa Genetics Incorporated’s float is 1.66%. The stock decreased 2.72% or $0.05 on November 23, hitting $1.79. About 63,766 shares traded hands. Atossa Genetics Inc (NASDAQ:ATOS) has declined 55.80% since April 22, 2016 and is downtrending. It has underperformed by 61.21% the S&P500.
Atossa Genetics Inc. is a clinical-stage pharmaceutical firm focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company has a market cap of $6.71 million. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It currently has negative earnings. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ and breast cancer.
Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 1.00, from 1 in 2016Q1. The ratio turned negative, as 4 funds sold all Atossa Genetics Inc shares owned while 2 reduced positions. 4 funds bought stakes while 2 increased positions. They now own 1.41 million shares or 3.81% more from 1.36 million shares in 2016Q1.
Geode Management holds 0% or 86,072 shares in its portfolio. Northern Tru holds 22,677 shares or 0% of its portfolio. Wells Fargo Mn holds 0% of its portfolio in Atossa Genetics Inc (NASDAQ:ATOS) for 29,000 shares. Renaissance Techs Llc accumulated 0% or 352,262 shares. Vanguard Grp Inc last reported 618,066 shares in the company. Kcg has 51,919 shares for 0% of their US portfolio. Blackrock Fund has invested 0% of its portfolio in Atossa Genetics Inc (NASDAQ:ATOS). Blackrock Institutional Trust Communications Na reported 111,034 shares or 0% of all its holdings. National Bank Of America Corp De owns 346 shares or 0% of their US portfolio. Nomura Hldg reported 44,073 shares or 0% of all its holdings. Pnc Svcs Grp Inc has 0% invested in the company for 4,350 shares. Moreover, Commonwealth Equity Svcs has 0% invested in Atossa Genetics Inc (NASDAQ:ATOS) for 40,000 shares. Royal Bank & Trust Of Canada has 0% invested in the company for 991 shares. Goldman Sachs Grp holds 0% or 41,827 shares in its portfolio.
Atossa Genetics Inc., incorporated on April 30, 2009, is a clinical-stage pharmaceutical firm focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. The Company’s second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. The Company’s medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory. It holds the worldwide exclusive rights to develop and commercialize AfTG for the treatment and prevention of hyperplasia of the breast. The active pharmaceutical ingredient in AfTG is Afimoxifene (4-hydroxytamoxifen), which is an active metabolite of tamoxifen. Afimoxifene is an anti-estrogen with an affinity for estrogen receptor that is up to approximately 50 fold higher compared with that of tamoxifen. AfTG is a transdermal gel formulation of Afimoxifene. It is evaluating AfTG for use in several patient populations, including high risk women as determined by family history; women with breast hyperplasia, and women with a biopsy showing either atypical hyperplasia or DCIS. AfTG can be dispensed from a metered-dose container. A total of over 16 Phase I and Phase II studies have been conducted in various indications in the United States, United Kingdom, France, Poland and Czech Republic.
More news for Atossa Genetics Inc (NASDAQ:ATOS) were recently published by: Quotes.Wsj.com, which released: “News Atossa Genetics Inc.ATOS” on October 02, 2012. Seekingalpha.com‘s article titled: “Ambitious Atossa Genetics Going After Two Breast Cancer Blockbusters” and published on December 10, 2015 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott